Genesis HealthCare (GEN) Tops Q2 EPS by 1c; offers guidance

Genesis HealthCare (NASDAQ: GEN) reported Q2 EPS of $0.62, $0.01 better than the analyst estimate of $0.61. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.19 billion.

GUIDANCE:

Genesis HealthCare sees Q3 2026 EPS of $0.62-$0.64, versus the consensus of $0.63. Genesis HealthCare sees Q3 2026 revenue of $1.22-1.24 billion, versus the consensus of $1.194 billion.

Genesis HealthCare sees FY2026 EPS of $2.51-$2.56, versus the consensus of $2.53. Genesis HealthCare sees FY2026 revenue of $4.92-4.97 billion, versus the consensus of $4.86 billion.

For earnings history and earnings-related data on Genesis HealthCare (GEN) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Boeing wins $2 billion satellite contract from DoW
• Worthington Industries (WOR) Misses Q4 EPS by 9c